FDA Grants Orphan Drug Designation to ASLAN003 in Acute Myeloid Leukemia

August 22, 2018 – The U.S. Food and Drug Administration (FDA) has granted ASLAN003 Orphan Drug designation as a treatment for acute myeloid leukemia (AML). ASLAN003 is an orally active, potent inhibitor of human dihydroorotate dehydrogenase (DHODH) that has the potential to be a first-in-class drug in AML. The FDA grants Orphan Drug designation to agents intended to treat a rare disease or condition that affects fewer than 200,000 individuals in the … (leggi tutto)